Nenasheva et al., 2017 - Google Patents
The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected miceNenasheva et al., 2017
View HTML- Document ID
- 16614010545048613569
- Author
- Nenasheva T
- Nikolaev A
- Diykanov D
- Sukhanova A
- Tcyganov E
- Panteleev A
- Bocharova I
- Serdyuk Y
- Nezlin L
- Radaeva T
- Adrianov N
- Rubtsov Y
- Lyadova I
- Publication year
- Publication venue
- PLoS One
External Links
Snippet
Mesenchymal stromal cells (MSC) have strong immunomodulatory properties and therefore can be used to control inflammation and tissue damage. It was suggested recently that MSC injections can be used to treat multi-drug resistant tuberculosis (TB). However, MSC …
- 210000004271 bone marrow stromal cells 0 title abstract description 261
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dall'Era et al. | Adoptive Treg cell therapy in a patient with systemic lupus erythematosus | |
Blazar et al. | Immune regulatory cell infusion for graft-versus-host disease prevention and therapy | |
Nenasheva et al. | The introduction of mesenchymal stromal cells induces different immunological responses in the lungs of healthy and M. tuberculosis infected mice | |
Das et al. | CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis | |
Bogunovic et al. | Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men | |
Akimova et al. | Helios expression is a marker of T cell activation and proliferation | |
Tornack et al. | Human and mouse hematopoietic stem cells are a depot for dormant Mycobacterium tuberculosis | |
Pleyer et al. | Mesenchymal stem and progenitor cells in normal and dysplastic hematopoiesis—masters of survival and clonality? | |
Lee et al. | Adoptive transfer of Treg cells combined with mesenchymal stem cells facilitates repopulation of endogenous Treg cells in a murine acute GVHD model | |
Eken et al. | Fingolimod alters tissue distribution and cytokine production of human and murine innate lymphoid cells | |
Kreiser et al. | Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo | |
Song et al. | Human mesenchymal stem cells derived from umbilical cord and bone marrow exert immunomodulatory effects in different mechanisms | |
Lösslein et al. | Monocyte progenitors give rise to multinucleated giant cells | |
Pezato et al. | Immunoregulatory effects of bone marrow‐derived mesenchymal stem cells in the nasal polyp microenvironment | |
Igarashi et al. | The lysophosphatidic acid receptor LPA4 regulates hematopoiesis-supporting activity of bone marrow stromal cells | |
Bézie et al. | IL-34 actions on FOXP3+ Tregs and CD14+ monocytes control human graft rejection | |
Tecchio et al. | Uncovering the multifaceted roles played by neutrophils in allogeneic hematopoietic stem cell transplantation | |
Naik et al. | Mouse bone marrow sca-1+ CD44+ mesenchymal stem cells kill avirulent mycobacteria but not mycobacterium tuberculosis through modulation of cathelicidin expression via the p38 mitogen-activated protein kinase-dependent pathway | |
Badillo et al. | Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft‐versus‐host disease | |
Bernatchez et al. | Hypersensitivity pneumonitis onset and severity is regulated by CD103 dendritic cell expression | |
Sattler et al. | Mucosal associated invariant T cells are differentially impaired in tolerant and immunosuppressed liver transplant recipients | |
Genardi et al. | Type II natural killer T cells contribute to protection against systemic methicillin-resistant staphylococcus aureus infection | |
Gail et al. | Complex interactions of cellular players in chronic Graft-versus-Host Disease | |
Wang et al. | The gut bacteria dysbiosis contributes to chronic graft-versus-host disease associated with a Treg/Th1 ratio imbalance | |
Li et al. | CCR7 expressing mesenchymal stem cells potently inhibit graft-versus-host disease by spoiling the fourth supplemental Billingham’s tenet |